BioSpace News Archive

Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that it will report fourth quarter 2022 earnings results for the period ended December 30, 2022, on Tuesday, February 28, 2023.

BD (Becton, Dickinson and Company) (NYSE: BDX) today announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) to help combat illness in the current and future respiratory virus seasons.

Vapotherm, Inc. today announced preliminary unaudited fourth quarter and full year 2022 net results.

Vapotherm, Inc. today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with a select group of institutional and accredited investors through a private placement financing (“PIPE”) for gross proceeds of approximately $23.0 million, before deducting fees to the placement agent and other offering expenses.

Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 01:00pm GMT / 08:00am ET.

EuMentis Therapeutics Inc., a privately-held biopharmaceutical company developing novel therapeutics for the treatment of neuropsychiatric diseases, today announced it has received an award from the United States Department of Defense (DoD) to develop a novel small molecule therapeutic targeting the extrasynaptic N-methyl-D-aspartate receptor (NMDAR) for the treatment of traumatic brain injury or “TBI.”

Karyopharm Therapeutics Inc. today announced it will report fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023.

Syneos Health® announced a strategic partnership with Equicare to use proXimity™, an innovative cloud-based software platform that accelerates the transfer of clinical trial subject data from multiple electronic health records to the sponsor’s electronic data capture systems.

iSpecimen Inc. today announced that over the course of the second half of 2022, the Company added and onboarded seven new biospecimen providers to the iSpecimen Marketplace ® , for both banked and prospectively collected specimens.

Annovis Bio, Inc. today announced approval for additional European clinical trial sites for the ongoing Phase 3 study of buntanetap for the treatment of Parkinson’s disease (“PD”).